bifidobacterium animalis
Cell therapyexperimental
Bifidobacterium is a genus of gram-positive, nonmotile, often branched anaerobic bacteria. They are ubiquitous inhabitants of the gastrointestinal tract though strains have been isolated from the vagina and mouth of mammals, including humans. Bifidobacteria are one of the major genera of bacteria that make up the gastrointestinal tract microbiota in mammals. Some bifidobacteria are used as probiotics. — Wikipedia
Clinical trial activity
153 trials · 191 clinical orgs · 0 marketing orgs
Phase 1
25
Phase 2
36
Phase 3
12
Phase 4
16
Earliest trial started Apr 1, 2003 (NCT00611299)
Timeline
Indications
Approved for
Studied for
- Antibiotic Prophylaxis · Phase 1
- Asthma · Phase 2/Phase 3
- Autism Spectrum Disorder · Phase 1/Phase 2
- Bacteremia · Phase 4
- Basal Ganglia Diseases · Phase 4
- Bifidobacterium · Phase 4
- Brain Diseases · Phase 4
- Carcinoma, Non-Small-Cell Lung · Phase 1/Phase 2
- Carcinoma, Renal Cell · Phase 1/Phase 2
- Carcinoma, Transitional Cell · Phase 4
- Cardiovascular Diseases · Phase 1
- Central Nervous System Diseases · Phase 4
- Cervix Uteri · Phase 2
- Child · Phase 1
- Colitis, Ulcerative · Phase 2
- Colonic Polyps · Phase 4
- Colonoscopy · Phase 2
- Colorectal Neoplasms · Phase 1/Phase 2
- Communicable Diseases · Phase 4
- Constipation · Phase 3
- Cystitis · Phase 4
- Dental Caries · Phase 4
- Dermatitis, Atopic · Phase 4
- Diabetes Mellitus, Type 1 · Phase 4
- Diabetes Mellitus, Type 2 · Phase 4
- Diarrhea · Phase 4
- Drug-Related Side Effects and Adverse Reactions · Phase 3
- Drugs, Investigational · Phase 4
- Dyspepsia · Phase 4
- Enterocolitis, Pseudomembranous · Phase 4
- Esophageal Neoplasms · Phase 1/Phase 2
- Febrile Neutropenia · Phase 2
- Feces · Phase 4
- Fever · Phase 2
- Gastritis · Phase 3
- Gastroenteritis · Phase 4
- Gastrointestinal Microbiome · Phase 2
- Graves Disease · Phase 1/Phase 2
- Healthy Volunteers · Phase 3
- Heart Diseases · Phase 2
- Heart Failure · Phase 2
- Helicobacter pylori · Phase 4
- HIV · Phase 1/Phase 2
- Hyperbilirubinemia, Neonatal · Phase 4
- Hypercholesterolemia · Phase 1
- Hyperglycemia · Phase 2
- Hypertension · Early Phase 1
- Infant, Premature · Phase 1
- Infections · Phase 2
- Influenza, Human · Phase 1
- Insulin Resistance · Phase 2
- Interleukin-17 · Phase 1/Phase 2
- Intestinal Diseases · Phase 1
- Intestinal Neoplasms · Phase 2
- Intra-Abdominal Fat · Phase 3
- Irritable Bowel Syndrome · Phase 4
- Kidney Failure, Chronic · Phase 2/Phase 3
- Kidney Transplantation · Early Phase 1
- Lichen Planus, Oral · Phase 2
- Live Birth · Phase 2
- Mania · Phase 2
- Melanoma · Phase 2
- Metabolic Syndrome · Phase 1/Phase 2
- Microsatellite Instability · Phase 1/Phase 2
- Movement Disorders · Phase 4
- Neoplasms · Phase 3
- Nervous System Diseases · Phase 4
- Neurodegenerative Diseases · Phase 4
- Neutropenia · Phase 2
- Non-alcoholic Fatty Liver Disease · Phase 1/Phase 2
- Obesity · Phase 3
- Oral Health · Phase 2/Phase 3
- Parkinson Disease · Phase 4
- Parkinsonian Disorders · Phase 4
- Pharyngitis · Phase 2
- Pneumonia · Phase 4
- Probiotics · Phase 4
- Respiratory Tract Infections · Phase 3
- Rhinitis, Allergic, Seasonal · Phase 3
- Signs and Symptoms, Digestive · Phase 1/Phase 2
- Stomatitis · Phase 3
- Stomatitis, Aphthous · Phase 2
- Subcutaneous Fat, Abdominal · Phase 3
- Surgical Wound Infection · Phase 4
- Triple Negative Breast Neoplasms · Phase 1/Phase 2
- Urinary Bladder Neoplasms · Phase 1/Phase 2
Mechanism of action
- microbiotaTissue restoration
microbiota tissue restoration
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaBifidobacterium ↗
- NCATS5307V7XW8I ↗
Also known as
- bb-12
- bifidobacteri
- bifidobacteria
- bifidobacteria animalis subsp. lactis bb-12
- bifidobacterium
- bifidobacterium
- bifidobacterium animalis
- bifidobacterium animalis a6
- bifidobacterium animalis lactis, bb-12
- bifidobacterium animalis ssp.
- bifidobacterium animalis ssp lactis
- bifidobacterium animalis ssp. lactis
- bifidobacterium animalis ssp. lactis 420
- bifidobacterium animalis subspecies lactis bb-12
- bifidobacterium animalis subspecies. lactis bb-12
- bifidobacterium animalis subsp. lactis
- bifidobacterium animalis subsp. lactis bb12
- bifidobacterium animalis subsp. lactis bb-12
- bifidobacterium animalis subsp. lactis bl-04
- bifidobacterium animalis subsp. lactis bpl1
- bifidobacterium animalis subsp. lactis strain bb-12
- bifidobacterium, bb-12
- bifidobacterium lactids
- bifidobacterium lactids - lbi07
- bifidobacterium lactis
- bifidobacterium lactis bb12
- bifidobacterium lactis bb-12
- bifidobacterium lactis bi-07
- b. lactis bb-12
- lab4
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06772090 | N/A | Dec 25, 2025 | University of Minnesota |
| NCT07287306 | N/A | Dec 10, 2025 | Wecare Probiotics Co., Ltd. |
| NCT07298824 | Phase 2 | Oct 1, 2025 | Nanchang University |
| NCT07157462 | N/A | Sep 1, 2025 | Alyatec, Winclove Bio Industries BV |
| NCT06720805 | N/A | Dec 1, 2024 | University of Roma La Sapienza |
| NCT06594406 | N/A | Oct 10, 2024 | Southern Medical University |
| NCT06216587 | N/A | Mar 20, 2024 | Wecare Probiotics Co., Ltd. |
| NCT06150287 | Early Phase 1 (Phase 1) | Feb 29, 2024 | State University of New York, Syracuse |
| NCT06238349 | Phase 4 | Jan 23, 2024 | Chongqing Medical University, Zhuhai Center for Maternal and Child Health Care |
| NCT06287931 | N/A | Jan 1, 2024 | Shandong Linglong Yingcheng Hospital |
| NCT06151210 | Phase 3 | Dec 31, 2023 | Dong-A Pharmaceutical |
| NCT06107049 | N/A | Oct 25, 2023 | Wecare Probiotics Co., Ltd. |
| NCT06125626 | Phase 2 | Jul 10, 2023 | University of Palermo |
| NCT07296718 | Phase 4 | May 15, 2023 | Islamia University of Bahawalpur |
| NCT06103253 | N/A | Apr 20, 2023 | Wecare Probiotics Co., Ltd. |
| NCT05791604 | N/A | Apr 1, 2023 | Fudan University |
| NCT05662514 | N/A | Jan 15, 2023 | Shandong University |
| NCT06325605 | N/A | Mar 1, 2022 | Tangshan Worker's Hospital |
| NCT05220124 | Phase 4 | Jan 5, 2022 | Tianjin Medical University |
| NCT04760353 | N/A | Nov 10, 2021 | Institut AllergoSan, KBC Rijeka; Medicinski fakultet Sveučilišta u Rijeci, University Hospital, Rijeka |
Showing 20 of 153 trials
Page 1 / 8
Organizations
Research & Development (191)
191 organizations
Page 1 / 10